Deadline Alert: PicS N.V. (PICS) Shareholders Who Lost
Glancy Prongay Wolke & Rotter LLP is reminding investors of PicS N.V. (PICS) that the deadline to file as lead plaintiff in a securities fraud lawsuit is August 4, 2026. The lawsuit alleges that PicS made materially false and misleading statements in its January 2026 IPO documents regarding its credit evaluation procedures and financial health, leading to a significant stock price drop. Investors who purchased PicS Class A common stock and suffered losses are urged to contact the firm.
Bronstein, Gewirtz & Grossman LLC Urges PicS N.V. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against PicS N.V. on behalf of investors who purchased securities during the company's January 30, 2026 IPO. The lawsuit alleges that PicS made materially false and misleading statements and failed to disclose significant deficiencies in its credit evaluation procedures, resulting in substantial reclassification of credit exposures and increased expected credit losses. Investors who suffered losses have until August 4, 2026, to request to be appointed lead plaintiff in the case.
Keysight Technologies (KEYS) Enhances GaN MMIC Design with New Collaboration
Keysight Technologies has partnered with WIN Semiconductors Corp. to improve GaN MMIC design, aiming to streamline the workflow and facilitate successful first-pass tapeouts for design firms. While this collaboration enhances growth prospects, the company's valuation metrics show a high P/E ratio of 58.11 and recent insider selling of $1.3 million, suggesting potential overvaluation despite a strong GF Score™ of 82. Investors are advised to consider these factors, including the 115.6% 52-week stock growth, before making investment decisions.
Viridian may have edge over Amgen in eye drug showdown, analysts argue
The FDA has approved Viridian Therapeutics' drug Lumvoa for thyroid eye disease, positioning it as a strong competitor to Amgen's Tepezza. Analysts believe Lumvoa's shorter infusion time, fewer infusions, and broader label covering both active and chronic thyroid eye disease give it a competitive advantage. While Lumvoa's pricing is similar to Tepezza, analysts project significant revenue growth by 2035 and Viridian is also developing an experimental subcutaneous treatment for chronic thyroid eye disease.
IBM Selects Stagwell as New Lead Creative Agency
IBM has selected Stagwell as its new lead creative agency, ending a long-standing partnership with WPP's Ogilvy. This strategic move aims to refine IBM's branding around enterprise artificial intelligence and enhance its marketing strategies. The company, which boasts a GF Score™ of 81/100, is positioning itself for future growth, although investors should note its modest financial strength rating and current market volatility.
UAL Maintained by Wells Fargo -- Price Target Raised to $165
Wells Fargo analyst Christian Wetherbee maintained an 'Overweight' rating on United Airlines Holdings (UAL) and raised the price target from $130.00 to $165.00, indicating strong confidence in the stock. Despite this positive analyst outlook, GuruFocus assesses UAL as 76.9% overvalued based on its GF Value™ of $78.37 versus the current price of $138.66. Additionally, insider activity shows $10.8 million in shares sold over the past three months, suggesting caution for investors.
Carahsoft Named 2025 Equinix AMER Distributor of the Year Partner Award Winner
Carahsoft Technology Corp. has been named the 2025 AMER Distributor of the Year by Equinix for the second consecutive year. This award recognizes Carahsoft's significant role in expanding Equinix's reach within the Public Sector by streamlining access to solutions and supporting partners. The collaboration has led to increased marketing engagement and partner-focused campaigns, driving digital transformation for government agencies.
Prologis presses Segro after $16.6B offer rejected
Prologis is intensifying its bid to acquire Segro, a London-based logistics warehouse operator, after its initial £12.6 billion ($16.6 billion) all-stock offer was rejected. Prologis argues the deal would unlock significant value for Segro shareholders through a 25% premium and access to Prologis' larger network and stronger balance sheet, while Segro maintains the offer is inadequate and opportunistic, undervaluing its business.
Applied Materials Stock's Best Month Since 1975: What's Driving AMAT? - Applied Materials (NASDAQ:AMAT) - Benzinga
Applied Materials (NASDAQ:AMAT) has experienced its best monthly rally since 1975, surging approximately 54% in June, driven by strong demand from the AI build-out. The company, which manufactures equipment for chip production, has seen significant upgrades in analyst earnings and revenue estimates. However, its valuation now trades at roughly double its long-run average, posing a risk of disappointment if expectations are not met.
Context on our country-by-country tax footprint
Microsoft has published its first "Public Country-by-Country Report" for fiscal year 2025, detailing its tax footprint across countries and regions covered by EU rules. The report provides transparency on revenue, profit, employee numbers, and income tax accrued and paid, with Microsoft emphasizing that it pays all taxes owed and that numbers require context due to varying tax laws and timing differences. The company also highlights its broader economic contributions through investments, job creation, and partnerships, noting that it paid $28.7 billion in corporate income taxes globally last year.


